Current and emerging treatment options for migraine and other primary headache disorders

Expert Review of Neurotherapeutics

Volumn 3, Issue 6, 2003, Pages 845-872

  Gladstone, Jonathan P ^a   Dodick, David W ^a  

^a MAYO CLINIC   (United States)

Author keywords

Abortive; Cluster; Migraine; Prophylactic; Tension type haedache; Triptan

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; BUTALBITAL; CAFERGOT; CAFFEINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CLOMIPRAMINE; DIHYDROERGOTAMINE MESILATE; DOXEPIN; FLUVOXAMINE; IBUPROFEN; ISOMETHEPTENE; KETOPROFEN; KETOROLAC; LITHIUM; METHYSERGIDE; MIANSERIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; PARACETAMOL; PEPPERMINT OIL; SINEGUAN; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TIZANIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUPUNCTURE; ACUTE KIDNEY FAILURE; ALLERGY; ALOPECIA; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; ASTHENIA; ASTHMA; ATRIOVENTRICULAR BLOCK; ATTENTION DEFICIT DISORDER; BLEEDING; BLOOD TOXICITY; BRADYCARDIA; CAPILLARY RESISTANCE; CAPSULE FILLING; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; CONFUSION; CONSTIPATION; CRYOTHERAPY; DEPENDENT PERSONALITY DISORDER; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DYSPEPSIA; ECONOMIC ASPECT; EDEMA; EPIDEMIOLOGICAL DATA; EXERCISE; FLUID RETENTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEALTH CARE COST; HEART PALPITATION; HEPATITIS; HUMAN; HYPERTENSION; HYPERTHERMIC THERAPY; HYPOTENSION; INSOMNIA; KIDNEY FAILURE; LEG CRAMP; LIVER TOXICITY; LOW DRUG DOSE; MANIPULATIVE MEDICINE; MASSAGE; MEMORY DISORDER; MENTAL INSTABILITY; META ANALYSIS; MIGRAINE; MOOD DISORDER; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; ORTHOSTATIC HYPOTENSION; OVARY POLYCYSTIC DISEASE; OVARY TUMOR; PANCREATITIS; PARESTHESIA; PATHOPHYSIOLOGY; PHYSIOTHERAPY; POLYURIA; PREVALENCE; PRURITUS; QUALITY OF LIFE; RASH; RELAXATION TRAINING; RESPIRATORY TRACT DISEASE; RESTLESSNESS; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SKIN MANIFESTATION; SKIN TINGLING; SKIN TOXICITY; SOMNOLENCE; STOMACH DISEASE; TACHYCARDIA; TASTE DISORDER; TENSION HEADACHE; THOUGHT DISORDER; THROMBOCYTOPENIA; THYROID DISEASE; TINNITUS; TOXICITY; TREATMENT PLANNING; TREMOR; ULCER; URINE RETENTION; URTICARIA; VERTIGO; VOMITING; XEROSTOMIA;

EID: 0344445407     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.6.845     Document Type: Review

References (210)

1. Rasmussen BK. Epidemiology of headache. Cephalalgia 15, 45-68 (1995).
2. Hu XH, Markson LE, Lipton RB et al. Burden of migraine in the United States: disability and economic costs. Arch Intern. Med. 159, 813-818 (1999).
3. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 8(Suppl. 7), 1-93 (1988).
4. Schwartz BS, Stewart WF, Simon D et al. Epidemiology of tension-type headache. JAMA 279, 381-383 (1998).
5. Rasmussen B, Jensen R, Schroll M et al. Epidemiology of headache in a general population: a prevalence study. J. Clin. Epidemiol. 44, 1147-1157 (1991).
6. Lipton RB, Hamelsky SW, Stewart WF. Epidemiology and impact of headache. Am. Acad. Neurol. 200 Syll. 7AC.001-1-7AC.001-30 (2001).
7. Rasmussen BK, Jensen R, Olesen J. Impact of headache on sickness absence and utilisation of medical services: a Danish population study. J. Epidemiol. Com. Health. 46, 443-446 (1992).
8. Schwart BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. J. Occup. Environ. Med. 39, 320-327 (1997).
9. Lavados P, Tenhamm E. Epidemiology of tension-type headache in Santiago, Chile: a prevalence study. Cephalalgia 18, 552-558 (1998).
10. Vandenheede M, Schoenen J. Central mechanisms in tension-type headaches. Curr. Pain Headache Rep. 6(5), 392-400 (2002). Current review of the pathophysiology of tension-type headache.
11. Bendtsen L. Central sensitization in tension-type headache - possible pathophysiological mechanisms. Cephalalgia 20, 486-508 (2000).
12. Jensen R. Peripheral and central mechanisms in tension-type headache: an update. Cephalalgia 23(Suppl. 1), 49-52 (2003).
13. Jensen R. Tension-type headache. Cur. Treat. Options Neurol. 3(2), 169-180 (2001).
14. Mathew N, Schoenen J. Acute Pharmacotherapy of tension-type headache. In The Headaches. Second Edition. Olesen J, Tfelt-Hansen, Welch MA (Eds). Lippincott, Williams and Wilkins, PA, USA, 661-666 (2000).
15. Sheftell FD. Role and impact of over-the-counter medications in the management of headache. Neurologic Clinics. 15(1), 187-200 (1997). Thorough review of the role of over-the-counter medications in primary headache disorders.
16. Stillman MJ. Pharmacotherapy of tension-type headache. Curr. Pain Headache Rep. 6(5), 408-413 (2002).
17. Redillas C, Solomon S. Prophylactic pharmacological treatment of chronic daily headache. Headache 40, 83-102 (2000).
18. Holroyd KA. Behavioral and psychologic aspects of the pathophysiology and management of tension-type headache. Curr. Pain Headache Rep. 6(5), 401-407 (2002). Highlights the role of nonpharmacologic modalities in the management of tension-type headache.
19. Vernon H, McDermain CS, Hagino C et al. Systematic review of randomized clinical trials of complimentary/alternative therapies in the treatment of tension-type and cervicogenic headache. Complement Ther. Med. 7, 142-155 (1999).
20. Edmeads J, Findlay H, Tugwell P et al. Impact of migraine and tension-type headache on life-style, consulting behaviour and medication use: a Canadian population survey. Can. J. Neurol. Sci. 20, 131-137 (1993).
21. Limmroth V, Katsarava Z, Diener HC. Acetylsalicylic acid in the treatment of headache. Cephalagia 19(6), 545-551 (1999).
22. Hersh EV, Moore PA, Ross GL. Over-the-counter analgesics and antipyretics: a critical assessment. Clin. Ther. 22(5), 500-548 (2000).
23. Langemark M, Olesen J. Effervescent ASA versus solid ASA in the treatment of TTH: a double-blind, placebo-controlled study. Headache 27, 90-95 (1987).
24. Peters BH, Fraim CJ, Masel BE. Comparison of 650 mg aspirin and 1000 mg acetaminophen with each other and with placebo in moderately severe headache. Am. J. Med. 74, 36-42 (1983).
25. Steiner TJ, Lange R, Voelker M. Aspirin in episodic tension-type headache: placebo-controlled dose-ranging comparison with paracetamol. Cephalalgia 23, 59-66 (2003).
26. Schachtel BP, Furey SA, Thoden WR. Nonprescription ibuprofen and acetaminophen in the treatment of tension-type headache. J. Clin. Pharmacol. 36(12), 1120-1125 (1996).
27. Prior MJ, Cooper KM, May LG et al. Efficacy and safety of acetaminophen and naproxen in the treatment of tension-type headache. A randomized, double-blind, placebo-controlled trial. Cephalalgia 22(9), 740-748 (2002).
28. Steiner TJ, Lange R. Ketoprofen (25 mg) in the symptomatic treatment of episodic tension-type headache: double-blind placebo-controlled comparison with acetaminophen (1000 mg). Cephalalgia 18, 38-43 (1998).
29. Lange R, Lentz R. Comparison of ketoprofen, ibuprofen and naproxen sodium in the treatment of tension-type headache. Drugs Explt. Clin. Res. 3, 89-96 (1995).
30. Schachtel BP, Furey SA, Thoden WR. Nonprescription ibuprofen and acetaminophen in the treatment of tension-type headache. J. Clin. Pharmacol. 1120-1125 (1996).
31. Dahlof CGH, Jacobs LD. Ketoprofen, paracetamol and placebo in the treatment of episodic tension-type headache. Cephalalgia 16, 117-123 (1996)
32. Packman B, Packman E, Doyle G et al. Solubilized ibuprofen: evaluation of onset, relief and safety of a novel formulation in the treatment of episodic tension-type headache. Headache 40(7), 562-567 (2000).
33. Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ 167(10), 1131-1137(2002).
34. Diamond S, Freitag FH. The use of ibuprofen plus caffeine to treat tension-type headache. Cur. Pain Headache Rep. 5(5), 472-478 (2001).
35. Migliardi JR, Armellino JJ, Friedman M et al. Caffeine as an analgesic adjuvant in tension-type headache. Clin. Pharmacol. Ther. 56(5), 576-586 (1994).
36. Ward N, Whitney C, Avery D et al. The analgesic effects of caffeine in headache. Pain 44, 151-155 (1991).
37. Silberstein SD, McCrory DC. Butalbital in the treatment of headache: history, pharmacology and efficacy. Headache 41, 953-967 (2001). Excellent overview of the role of butalbital in headache treatment.
38. Solomon S. Butalbital-containing agents: should they be banned? No. Curr. Pain Headache Rep. 6(2), 147-150 (2002).
39. Young WB, Siow HC. Should butalbital-containing analgesics be banned? Yes. Curr. Pain Headache Rep. 6(2), 151-155 (2002).
40. Lipton RB, Stewart WF, Cady R et al. 2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 40(10), 783-791 (2000).
41. Leston JA. Migraine and tension-type headache are not separate disordes. Cephalalgia 16, 217-220 (1996).
42. Rasmussen BK. Migraine and tension-type headache are separate disorders. Cephalalgia 16, 220-223 (1996).
43. Rothrock JF. What's in a name? Tension-type headache versus migraine. Curr. Pain Headache Rep. 5(5), 463-466 (2001).
44. Schattner P, Randerson D. Tiger Balm as a treatment of tension headache. A clinical trial in general practice. Aust. Fam. Physician 25(2), 216-220 (1996).
45. Gobel H, Fresenius J, Heinze A et al. Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tension type. Nervenarzt. 67(8), 672-681(1996).
46. Silberstein SD, Lipton RB. Chronic daily headache. Curr. Opin. Neurol. 13, 277-288 (2000).
47. Holroyd KA, O'donnell FJ, Stensland M et al. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy and their combination. JAMA 285(7), 2208-2215 (2001). Important study demonstrating the synergistic effect of nonpharmacologic and pharmacologic modalities.
48. Langemark M, Loldrup D, Bech P et al. Clomipramine and mianserin in the treatment of chronic tension headache: a double-blind, controlled study. Headache 30, 118-121 (1990).
49. Manna V, Bolino F, DiCicco L. Chronic tension-type headache: a placebo-controlled double-blind crossover study. Headache 34, 44-49 (1994).
50. Rollnik JD, Tanneberger O, Schubert M et al. Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache 40, 300-305 (2000).
51. Evers S, Rahmann A, vollmer-Haase J et al. Treatment of headache with botulinum toxin A - a review according to evidence based medicine criteria. Cephalalgia 22(9), 699-710 (2002).
52. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A (BOTOX) for chronic daily headache: a randomized placebo-controlled, parallel design study. American Headache Society 44th Annual Scientific Meeting. Seattle, WA, USA, June 21-24 (2002).
53. Saper Jr, Laker AE, Cantrell DT et al. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 42(6), 470-482 (2002).
54. Ashina M. Nitric oxide synthase inhibitors for the treatment of chronic tension-type headache. Expert Opin. Pharmacother. 3(4), 395-399 (2002).
55. Hamelsky SW, Stewart WF, Lipton RB. Epidemiology of migraine. Curr. Pain Headache Rep. 5 (2). 189-194 (2001).
56. 57) Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N. Engl. J. Med. 346(4), 157-170 (2002). State of the art review of migraine pathophysiology and treatment.
57. Scher A, Stewart W, Lipton RB. Migraine and headache: a meta-analytic approach. In: Epidemiology of Pain. Crombie I (Ed.). IASP Press, Seattle, WA, USA, 159-170 (1999).
58. Lipton R, Hamelsky S, Kolodner K et al. Migraine, quality of life and depression: a population-based case-control study. Neurology 55, 629-635 (2000).
59. Steiner TJ, Lipton RB, Liberman JN et al. Work and family impact of migraine: a population-based case-control study. Neurology 52(Suppl. 2), A470-A471 (1999).
60. Lipton RB, Stewart WF, Diamond S et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41(7), 646-657 (2001).
61. Aurora SK. Pathophysiology of migraine headache. Curr. Pain Headache Rep. 5(2), 179-182 (2001). Current review of migraine pathophysiology.
62. May A. Headache: lessons learned from functional imaging. Br. Med. Bull. 65, 223-234 (2003).
63. Hadjikhani N, Sancez Del Rio M, Wu O et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc. Natl Acad Sci. USA 98(8), 4687-4692 (2001).
64. Bolay H, Reuter U, Dunn AK et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med. 8(2), 136-142 (2002).
65. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Neurology 55, 754-762 (2000). US Headache Consortium guidelines for the pharmacologic treatment of migraine.
66. Lipton RB, Stewart WF, Stone AM et al. Stratified care versus step care strategies for migraine. The Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA 284(20), 2599-2605 (2000). Important study illustrating the benefits of the stratified care treatment strategy.
67. Lipton RB, Stewart WF, Sawyer J. Stratified care is a more effective migraine treatment strategy than stepped care: results of a randomized clinical trial. Neurology 54(Suppl. 3), A14 (2000).
68. Cady R, Dodick DW. Migraine headache: a new look at diagnosis, treatment and efficacy evaluation. Mayo Clinic Proc. 77(3), 255-261 (2002).
69. Schoenen J. When should triptans be taken during a migraine attack? CNS Drugs 15(8), 583-587 (2001).
70. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 123, 1703-1709 (2001).
71. Burstein R, Collins B, Bajwa Z et al. Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: clinical and preclinical evidence. Headache 42, 390 (2002).
72. Winner P, Mannix L, McNeal S et al. Treatment of migraine at the first sign of pain: prospective, double-blind, placebo-controlled, multicenter studies of sumatriptan 50 mg and 100 mg versus placebo. Neurology 58(Suppl. 3), A415 (2002).
73. Klapper JA, Charlesworth B, Jergenson AP et al. Treatment of mild migraine with oral zolmitriptan 2.5 mg prevents progression to more severe migraine and reduces the impact on normal activities in patients with significant migraine-related disability. Neurology 58(Suppl. 3), A291-A292 (2002).
74. Burstein R, Collins B, Bajwa Z et al. Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: clinical and preclinical evidence. Headache 42, 390 (2002).
75. Martin VT, Behbehani MM. Toward a rational understanding of migraine trigger factors. Med. Clin. North Am. 85(4), 911-941 (2001).
76. Limmroth V, Przywara S. Analgesics. In: Drug Treatment of Migraine and Other Headaches. Diener HC (Ed.). Monogr. Clin. Neurosci. Basel, Switzerland. 17, 30-43 (2000).
77. Limmroth V, Przywara S. Analgesics. In: Drug Treatment of Migraine and Other Headaches. Diener HC (Ed.). Monogr. Clin. Neurosci. Basel, Switzerland. 17, 30-43 (2000).
78. Boureau F, Joubert JM, Lasserre V et al. Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia 14(2), 156-161 (1994).
79. MacGregor EA, Dowson A, Davies PT. Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Headache 42, 249-255 (2002).
80. Lange R, Schwarz JA, Hohn M. Acetysalicylic acid effervescent 1 000mg (Aspirin) in acute migraine attacks; a mutlicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 20, 663-667 (2000).
81. Tfelt-Hansen P, Henry P, Mulder LJ et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 346, 923-926.
82. Kaube H, Hoskin KL, Goadsby PJ. Acetylsalicylic acid inhibits cerebral central cortical vasodilation caused by superior sagittal sinus stimulation in the cast. Eur. J. Neurol. 1, 141-146 (1994).
83. Larsen BH, Christiansen LV, Andersen B et al. Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine. Acta Neurol. Scand 81, 464-467 (1990).
84. Lipton RB, Baggish JS, Stewart WF et al. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern. Med. 160(22), 3486-3492 (2000)..
85. Codispori JR, Prior MJ, Fu M et al. Efficacy of nonprescription doses of ibuprofen for treating migraine headache. Headache 41(7), 665-679 (2001).
86. Kellstein DE, Lipton RB, Geetha R et al. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia 20(4), 233-243 (2000).
87. Shrestha M, Singh R, Moreden J et al. Ketorolac vs. chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. Arch Intern. Med. 156(15), 1725-1728 (1996).
88. Rasmussen MK, Binzer M. Nonsteroidal anti-inflammatory drugs in the treatment of migraine. Curr. Med. Res. Opin. 17(Suppl. 1), 26-29 (2001).
89. Did M, Massiou H, Weber M et al. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology 58(11), 1660-1665 (2002).
90. Lipton RB, Stewart WF, Ryan RE Jr et al. Efficacy and safety of acetaminophen, aspirin and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol. 55(2), 210-217 (1998).
91. Freitag FG, Cady R, DiSerio F et al. Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. Headache 41(4), 391-398 (2001).
92. Goldstein J, Gawel MJ, Winner P et al. Comparison of Butorphanol nasal spray with Fiorinal with Codeine in the treatment of migraine. Headache 38, 516-522 (1998).
93. Silbersrein SD, McCrory DS. Opioids. Cephalalgia 20, 854-864 (2000). Excellent overview of the role of opioids in the management of primary headache disorders.
94. Boureau F, Joubert JM, Lasserre V et al. Double-blind comparison of an acetaminophen 400mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine. Cephalalgia 14(2), 156-161 (1994).
95. Ziegler DK. Opioids in headache treatment. Is there a role? Neurol. Clin. 15(1), 199-207 (1997).
96. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology and efficacy. Headache 43, 144-166(2003).
97. Matthew NT. Dosing and administration of ergotamine and dihydroergotamine. Headache 37(Suppl. 1), S26-S32 (1997).
98. Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache 37(Suppl. 1), S33-S41 (1997).
99. Bigal ME, Tepper SJ. Ergotamine and digydroergotamine: a review. Curr. Pain Headache Rep. 7(1), 55-62 (2003). Current review summarizing the role of ergotamine and dihydroergotamine (DHE) in migraine therapy.
100. Cady RK, Wendt JK, Kirchner JF, et al. Treatment of acute migraine with sc. sumatriptan. JAMA 265, 2831-2835 (1991).
101. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N. Engl. J. Med. 325, 316-321 (1991).
102. Dahlof C. Sumatriptan nasal spray in the acute treatment of migraine. A review of clinical studies. Cephalalgia 19, 769-778 (1999).
103. Pfaffenrath V, Cunin G, Sjonell G et al. Efficacy and safety of sumatripran tablets in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache 38, 184-190 (1998).
104. Sargent J, Kirchner JR, Davis R et al. Oral sumatriptan is effective and well-tolerated for the acute treatment of migraine: Results of a multicenter study. Neurology 45 (Suppl. 7), S10-S14 (1995).
105. Cutler N, Mushet GR, Davis R et al. Oral sumatriptan for the acute treatment of migraine: Evaluation of three dosage strengths. Neurology 45(Suppl. 7), S5-S9 (1995).
106. Adelman JU, Sharfman M., Johnson R. et al. Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use and patients satisfaction with medication in nurses with migraine. Am. J. Man. Care 2, 1407-1416 (1996).
107. Maassen VanDenBrink A, Reekers M, Bax WA et al. Circulation 98(1), 25-30 (1998).
108. Nappi G, Sandrini G, Sances G et al. Tolerability of the triptans: clinical implications. Drug Safety 26(2), 93-107 (2003).
109. Welch KMA, Mathew NT, Stone P et al. Tolerability of sumatriptan: clinical trials and postmarketing experience. Cephalalgia 8, 687-695 (2000).
110. Evans RW, Martin V. Asessing cardiac risk prior to the use of triptans. Headache 40, 599-602 (2000).
111. Tfelt-Hansen P, Dr Vries P, Saxena PR. Triptans in migraine. a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60(6), 1259-1287 (2000).
112. Dahlöf CGH, Dodick DW, Dowson AJ, Pascual J. How does Almotriptan compare to other triptans? A review of data from placebo-controlled clinical trials. Headache 42(2), 99-113 (2002).
113. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358, 1668-1675 (2001). Detailed meta-analysis reviewing the currently available triptans.
114. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 22, 491-512 (2002). Excellent overview of the currently available options for prophylactic treatment of migraine.
115. Krymchantowski AV, Bigal ME, Moreira PF et al. New and emerging prophylactic agents for migraine. CNS Drugs 16(9), 611-634 (2002). Detailed summary of the current and emerging prophylactic agents for migraine.
116. Limmroth V, Mummel P. Migraine Prophylaxis: β-blockers. In: Drug Treatment of Migraine and Other Headaches. Diener HC (Ed.). Monogr. Clin. Neurosci. Basel, Switzerland, 17, 256-268 (2000).
117. Mathew NT, Silberstein SD. Anticonvulsants in migraine prophylaxis. In: Drug Treatment of Migraine and Other Headaches. Diener HC (Ed.). Monogr. Clin. Neurosci. Basel, Switzerland 17, 288-298 (2000).
118. Wheeler SD. Antiepileptic drug therapy in migraine headache. Curr. Treat. Op. Neurology 4, 383-394 (2002).
119. Cutrer FM. Antiepileptic drugs: how they work in headache. Headache 41 (Suppl. 1), S3-S10 (2001).
120. Mathew NT. Antiepileptic drugs in migraine prevention. Headache 41(Suppl. 1), S18-S24 (2001).
121. Freitag FG, Collins SD, Carlson BA et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 58, 1652-1659 (2002).
122. Mathew NT, Rapoport A, Saper J et al. Efficacy of gabapentin in migraine prophylaxis. Headache 41(2), 119-128 (2001).
123. Schoonman GG, Wiendels NJ, Ferrari MD. Gabapentin in migraine prophylaxis: is it effective and well-tolerated? Headache 42(3), 235 (2002).
124. Storey JR, Calder CS, Hart De et al. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 41, 968-975 (2001).
125. Mathew NT, Schmitt J, Jacobs D et al. Topiramate in migraine prevention (MIGR-001): effect on migraine frequency. Neuorology. 60(5)(Supp. 1), A336.
126. Toda N, Tfelt-Hansen P. Calcium channel antagonist in migraine prophylaxis. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen, Welch MA (Eds). Lippincott, Williams and Wilkins, PA, USA, 477-482 (2000).
127. Diener HC. Flunarizine for migraine prophylaxis. In: Drug Treatment of Migraine and Other Headaches. Diener HC (Ed.). Monogr. Clin. Neurosci. Basel, Switzerland 17, 269-278 (2000).
128. Silberstein SD. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin. Pharamcother. 2(10), 1649-1654 (2001).
129. Silberstein S, Mathew N, Saper J et al. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 40(6), 445-450 (2000).
130. Barrientol S, Chana P. Efficacy and safety of botulinum toxin type A (BOTOX) in the prophylactic treatment of migraine. American Headache Society 44th Annual Scientific Meeting. Seattle, WA, USA. June 21-23 (2002).
131. Eross EG, Dodick DW. The effects of botulinum toxin type A on disability in episodic and chronic migraine. American Headache Society 44th Annual Scientific Meeting. Seattle, WA, USA, June 21-23, (2002).
132. Bluring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA 264(13), 1711-13 (1990).
133. Peto R, Gray R, Collins R et al. Randomized trial of prophylactic daily aspiring in British male doctors. Br. Med. J. 296, 313-316 (1988).
134. Bensenor IM, Cook NR, Lee IM et al. Low-dose aspirin for migraine prophylaxis in women. Cephalalgia 21(3), 175-183 (2001).
135. Diener HC, Hartung E, Chrubasik J et al. A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group Phase III study. Cephalalgia 21(2), 120-128 (2001).
136. Schrader H, Stovener LJ, Helde G et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo-controlled, crossover study. Br. Med. J. 322(7277), 19-22 (2001).
137. Etminan M, Levine M, Tomlinson G et al. Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis. Am. J. Med. 112, 642-646 (2002).
138. Tronvik E, Stovner LJ, Helde G et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker - a randomized controlled trial. JAMA 289, 65-69 (2003).
139. Pitder MH, Vogler BK, Ernst E. Feverfew for preventing migraine. Cochrane Database Sys. Rev. 3, CD002286 (2000).
140. Pfaffenrath V, Diener HC, Fischer M et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis - a double-blind, multicenter, randomized, placebo-controlled dose-response study. Cephalalgia 22(7), 523-532 (2002).
141. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis - a randomized controlled trial. Neurology 50, 466-470 (1998).
142. Pfaffenrath V, wessely P, Meyer C et al. Magnesium in the prophylaxis of migraine - a double-blind, placebo-controlled study. Cephalalgia 16, 436-440 (1996).
143. Peikert A, Wilimzig C, Kohne-Wolland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multicenter, placebo-controlled and double-blind randomized study. Cephalalgia 16, 257-263 (1996).
144. Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraine. Clin. Neurosci. 5(1), 24-27 (1998).
145. Rozen TD, Oshinsky ML, Gebeline CA et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 22, 137-141 (2002).
146. Grossmann M, Schmidramsl H. An extract of petasites hybridus is effective in the prophylaxis of migraine. Int. J. Clin. Pharmacol. Ther. 38(9), 430-435 (2000).
147. Dodick DW, Tozen TD, Goadsby PJ et al. Cluster headache. Cephalalgia 20, 787-803 (2000). Detailed overview of the epidemiology, pathophysiology and treatment of cluster headache.
148. Ekbom K, Hardebo JE. Cluster headache: aetiology, diagnosis and management. Drugs 62(1), 61-69 (2002).
149. Dodick DW, Capobianco DJ. Treatment and management of cluster headache. Cur. Pain Headache Rep. 5(1), 83-91 (2001).
150. Aurora SK. Etiology and pathogenesis of cluster headache. Curr. Pain Headache Rep. 6(1), 71-75 (2002).
151. Pringsheim T. Cluster headache: evidence for a disorder of circadian rhythm and hypothalamic function. Can. J. Neurol. Sci. 29(1), 33-40 (2002).
152. Russel MB. Genetic epidemiology of migraine and cluster headache. Cephalalgia 17, 683-701 (1997).
153. Leone M, Bussone G. A review of hormonal findings in cluster headache. Evidence for hypothalamic involvement. Cephalalgia 13, 309-317 (1993).
154. May A, Bahra A, Buchel C et al. Hypothalamic activation in cluster headache attacks. Lancet 352, 275-278 (1998).
155. May A, Ashburner J, Buchel C et al. Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nat. Med. 5, 836-838 (1999).
156. May A, Bahra A, Buchel C et al. PET and MRA findings in cluster headache and MRA in experimental pain. Neurology 55, 1328-1335 (2000).
157. Rozen TD. New treatments in cluster headache. Cur. Neruol. Neurosci. Rep. 2, 114-121 (2002).
158. Ekbom K. Treatment of acute cluster headache with sumatriptan. N. Engl. J. Med. 325, 322-326 (1991).
159. Gobel H, Linder V, Heinze A et al. Acute therapy for cluster headache with sumatriptan: findings of a one-year long-term study. Neurology 51, 908-911 (1998).
160. Van Vliet JA, Bahra A, Martin V et al. Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. Neurology 60, 630-633 (2003).
161. Bahra A, Gawel MJ, Hardebo JE et al. Oral zolmitriptan is effective in the acute treatment of cluster. Neurology 54, 1832-1839 (2000).
162. Fogan L. Treatment of cluster headache. A double-blind comparison of oxygen air inhalation. Arch Neurol. 42, 362-363 (1985).
163. Kudrow L. Response of cluster headache attacks to oxygen inhalation. Headache 21, 1-4 (1981).
164. Robbins L. Intranasal lidocaine for cluster headache. Headache 35, 83-84 (1995).
165. Andersson PG, Jespersen LT. Dihydroergotamine naal spray in the treatment of attacks of cluster headache. Cephalalgia 6, 51-54 (1986).
166. Rozen TD. Olanzapine as an abortive agent for cluster headache. Headache 41, 813-816 (2001).
167. Anthony M, Daher BN. Mechanisms of action of steroids in cluster headache. In: New Advances in Headache Research 2. Rose FC (Ed.). Smith Gordon, London, UK, 271-274 (1992).
168. Mather PJ, Silberstein SD, Schulman EA et al. The treatment of cluster headache with repetitive intravenous dihydroergotamine. Headache 31, 525-532 (1991).
169. Mulder LJ, Spierings EL. Naratriptan in the preventive treatment of cluster headache. Cephalalgia 22, 815-817 (2002).
170. Leone M, D'Amico D, Artanasio A et al. Verapmail is an effective prophylactic for cluster headache: results of a double-blind multicenter study versus placebo. In: Cluster Headache & Related Conditions. Olesen J, Goadsby PJ (Eds). Oxford University Press, Oxford, UK, 296-299 (1999).
171. Stiener TJ, Hering R, couturier ECM et al. Double-blind placebo-controlled trial of lithium in episodic cluster headache. Cephalalgia 17, 673-675 (1997).
172. Bussone G, Leone M, Peccarisi C. Double-blind comparison of lithium and verapamil in cluster headache prophylaxis. Headache 30, 411-417 (1990).
173. Curran DA, Hinterburger H, Lance JW. Methysergide. Res. Clin. Stud. Head. 1, 74-122 (1967).
174. Rozen TD. Antiepileptic drugs in the management of cluster headache and trigeminal neuralgia. Headache 41 (Supp. 1), S24-S32 (2001).
175. El Amrani M, Masssiou H, Bousser MG. A negative trial of sodium valproate in cluster headache: methodological issues. Cephalalgia 22, 205-208 (2002).
176. Lainez MJ, Pascual K, Santonja JM et al. Topiramate in the prophylactic treatment of cluster headache. Cephalalgia 21, 500 (2001).
177. Forderreuther S, Mayer M, Straube A. Treatment of cluster headache with topiramate: effects and side effects in five patients. Cephalalgia 22(3), 186-189 (2002).
178. Wheeler SD, Carrazana EJ. Topiramate-treated cluster headache. Neurology 53(1), 234-236(1999)
179. McGeeney BE. Topiramate in the treatment of cluster headache. Curr. Pain Headache Rep. 7(20), 135-138 (2003).
180. Leandri M, Luzzani M, Cruccu G et al. Drug-resistant cluster headache responding to gabapentin: a pilot study. Cephalalgia 21, 744-746 (2001).
181. Leone M, Damico D, Moschiano F et al. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia 16, 494-496 (1996).
182. Pringsheim T, Magnoux E, Dobson CF et al. Melatonin as adjunctive therapy in the prophylaxis of cluster headache: a pilot study. Headache 42(8), 787-792 (2002).
183. Marks DR, Rapoport A, Padla D et al. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache. Cephalalgia 13(2), 114-116 (1993).
184. Saper JR, Klapper J, Matthew NT et al. Intranasal civamide for the treatment of episodic cluster headaches. Arch Neurol. 59(6), 990-994(2003).
185. Markley HG. Topical agents in the treatment of cluster headache. Curr. Pain Headache Rep. 7(2), 139-143(2003).
186. Rozen TD. Interventional treatment for cluster headache: a review of the options. Curr. Pain Headache Rep. 6(1), 57-64 (2002).
187. Peres MF, Stiles MA, Siow HC et al. Greater occipatal nerve blockage for cluster headache. Cephalalgia 22(7), 520-522 (2002).
188. Leone M, Franzini A, D'Amirco D et al. Stereotactic electrode implant in inferior posterior hypothalamic gray matter to relieve intractable chronic cluster headache: the first reported case. Neurology 56(Suppl. 3), A218 (2001).
189. Jarrar RG, Black DF, Dodick DW et al. Outcome of trigeminal nerve section in the treatment of chronic cluster headache. Neurology 60(8), 1360-1362 (2003).
190. Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study with diagnostic implications. Neurology 58, 354-361 (2002).
191. International Headache Society Committee on Clinical Trials. Guidelines for trials of drug treatments in tension-type headache. Cephalalgia 15, 165-179 (1995).
192. Ashina M, Bendsten L, Jensen R et al. Effect of inhibition of nitric oxide synthase on chronic tension-type headache: a randomised cross-over trial. Lancet 353, 287-289 (1999).
193. Mucke H. Therapies in development for the treatment of migraine. Expert Opin. Investig. Drugs 11(12), 1813-1820 (2002). Current overview of the potential therapeutic targets under active investigation for migraine abortive therapy.
194. May A, Goadsby PJ. Pharmacological opportunities and pitfalls in the therapy of migraine. Curr. Opin. Neurol. 14, 341-346 (2001).
195. 1D agonist, in patients with acute migraine. Cephalalgia 21, 727-732 (2001).
196. 1D receptor agonist PNU-142633. Cephalalgia 22(10), 799-806.
197. Goadsby PJ. Novel targets for migraine therapy. Cephalalgia 21, 267 (2001).
198. May A, Goadsby PJ. Substance P receptor antagonists in the therapy of migraine. Expert Opin. Investig. Drugs 10(4), 673-678 (2001).
199. Thomsen LL, Olesen J. Nitric oxide in primary headaches. Curr. Opin. Neurol. 14, 315-321 (2001).
200. Lanssen LH, Ashina M, Christiansen I et al. Nitric oxide synthase inhibition in migraine. Lancet 349, 401-402 (1997).
201. Akerman S, Williamson DJ, Kaube H et al. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br. J. Pharmacol. 137(1), 62-68 (2002).
202. Reuter U, Chiarugi A, Bolay H et al. Nuclear factor-κB as a molecular target for migraine therapy. Ann. Neurol. 51(4), 507-516 (2002).
203. Doods H. Development of CGRP antagonists for the treatment of migraine. Curr. Opin. Investig. Drugs 2(9), 1261-1268 (2001).
204. Edvinsson L. Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications. CNS Drugs 15(10), 745-753.
205. Brain SD, Poyner DR, Hill RG. CGRP receptors: a headache to study but will antagonists prove therapeutic in migraine. Trends Pharmacol. Sci. 23(2), 51-53 (2002).
206. Lassen LH, Haderslev PA, Jacobsen VB et al. CGRP may play a causative role in migraine. Cephalalgia 22(1), 54-61 (2002).
207. Humphrey PP, Bland-Ward MM et al. Inhibition of trigeminal nociceptive afferents by adenosine A1 receptor activation: a novel approach towards the
208. Goadsby PJ, Hoskin HL, Storer RJ et al. Adenosine A1 receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 125(Pt 6), 1392-1401 (2002).
209. Ramadan N, Sang C et al. IV LY-293558, an AMPA/KA receptor antagonist, is effective in migraine. Cephalalgia 21, 267 (2001).
210. Campbell JK, Penzien DB, Wall EM. Evidence-based guidelines for migraine headache: behavioral and physical treatments. AAN Headache Guidelines. US Headache Consortium www.aan.com (2000). US Headache Consortium guidelines for nonpharmacologic management of migraines.